Related Articles
Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS
Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy
Preliminary evaluation of the potential role of β‑elemene in reversing erlotinib‑resistant human NSCLC A549/ER cells
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
GBP1 promotes erlotinib resistance via PGK1‑activated EMT signaling in non‑small cell lung cancer